Provision of antiretroviral therapy in south africa: The nuts and bolts

Antiviral Therapy

Volumn 19, Issue , 2014, Pages 105-116

  Bekker, Linda Gail ^a   Venter, Francois ^b   Cohen, Karen ^a   Goemare, Eric ^a,c   Van Cutsem, Gilles ^a,c   Boulle, Andrew ^a   Wood, Robin ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

DISEASE TRANSMISSION; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE FACILITY; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; MIXED INFECTION; PATIENT CARE; PRACTICE GUIDELINE; PUBLIC HEALTH; REVIEW; SOUTH AFRICA; TREATMENT INDICATION; TUBERCULOSIS; ECONOMICS; GOVERNMENT; HEALTH CARE DISPARITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; MANPOWER; PUBLIC-PRIVATE PARTNERSHIP; SUPPLY AND DISTRIBUTION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; GOVERNMENT PROGRAMS; HEALTHCARE DISPARITIES; HIV INFECTIONS; HUMANS; LIFE EXPECTANCY; PUBLIC HEALTH; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; SOUTH AFRICA;

EID: 84922151135     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2905     Document Type: Review

References (128)

1. th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013). 30 June-3 July 2013, Kuala Lumpur, Malaysia. Abstract MOSY0105. (Accessed 20 August 2013.) Available from http://pag.ias2013.org/ session.aspx?s=63
2. UNAIDS. UNAIDS report on the global AIDS epidemic 2012. (Accessed 15 August 2013.) Available from http:// www.unaids.org/en/media/unaids/contentassets/documents/ epidemiology/2012/gr2012/20121120-UNAIDS-Global- Report-2012-with-annexes-en.pdf
3. Blecher M, Kollipara A, DeJager P, Zulu N. Health financing. In Paradath A, English R (editors). South African Health Review 2011. Cape Town, South Africa: Health Systems Trust 2011.
4. Pillay Y, White C, McCormick N. How times have changed: HIV and AIDS in South Africa in 2011. S Afr Med J 2012; 102:77-78.
5. Johnson L. Access to antiretroviral treatment in South Africa, 2004-2011. S Afr J HIV Med 2012; 13:22-27.
6. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. (Updated 30 June 2013. Accessed 15 February 2014.) Available from www.who.int/hiv/pub/guidelines/ arv2013/download/en/
7. Venter WD, Barker PM. Raising the CD4 initiation threshold with our eyes wide open. S Afr Med J 2013; 103:834.
8. Trading Economics. South African GDP growth rate. (Accessed 21 February 2014.) Available from http://www. tradingeconomics.com/south-africa/gdp-growth
9. World Bank. The Gini Index data bank. (Accessed 23 May 2014.) Available from http://data.worldbank.org/indicator/ SI.POV.GINI
10. Motsoaledi A. Health budget speech by Dr Aaron Motsoaledi, MP, Minister of Health, National Assembly, 2013. (Accessed 23 May 2014.) Available from http://www. gov.za/speeches/view.php?sid=36484
11. Hecht R, Stover J, Bollinger L, et al. Financing of HIV/AIDS programme scale-up in low-income and middle-income countries, 2009-31. Lancet 2010; 376:1254-1260.
12. th Meeting of the Budget Monitoring Forum. Section 27. (Accessed 23 May 2014.) Available from http://www.section27.org.za/bemf/
13. Bateman C. NHI consensus: fix the existing system or risk failure. S Afr Med J 2010; 100:791-793.
14. The Global Fund To Fight AIDS, Tuberculosis and Malaria. Global Fund's Executive Director visits President of South Africa. (Updated 7 March 2013. Accessed 20 August 2013.) Available from http://www.theglobalfund.org/en/ mediacenter/newsreleases/2013-03-07-Global-Fund- Executive-Director-Visits-President-of-South-Africa/
15. Johnson LF, Hallett TB, Rehle TM, Dorrington RE. The effect of changes in condom usage and antiretroviral treatment coverage on human immunodeficiency virus incidence in South Africa: a model-based analysis. J R Soc Interface 2012; 9:1544-1554.
16. Butler A. Condom use on the rise, but more can be done. (Updated 7 June 2013. Accessed 7 June 2013.) Available from http://www.bdlive.co.za/opinion/ columnists/2013/06/07/condom-use-on-the-rise-but-more-can-be-done
17. Cullinan K, Thom A (editors). The virus, vitamins and vegetables: the South African HIV/AIDS mystery. Cape Town: Jacana Media 2010.
18. Venter F. HIV treatment in South Africa: the challenges of an increasingly successful antiretroviral programme: service delivery. South African Health Review 2012; 2012:37-47.
19. Chigwedere P, Seage GR, Gruskin S, Lee TH, Essex M. Estimating the lost benefits of antiretroviral drug use in South Africa. J Acquir Immune Defic Syndr 2008; 49:410-415.
20. McNeil J. The HIV/AIDS crisis emerges: responses of the apartheid government. (Accessed 21 February 2014.) Available from http://www.sahistory.org.za/topic/history-official-government-hivaids-policy-south-africa
21. Coovadia H, Jewkes R, Barron P, Sanders D, McIntyre D. The health and health system of South Africa: historical roots of current public health challenges. Lancet 2009; 374:817-834.
22. Dorrington RE, Johnson LF, Bradshaw D, Daniel T. The demographic impact of HIV/AIDS in South Africa. National and provincial indicators for 2006. Cape Town, South Africa: Centre for Actuarial Research, South African Medical Research Council and Actuarial Society of South Africa. (Accessed 21 February 2014.) Available from http:// www.mrc.ac.za/bod/DemographicImpactHIVIndicators.pdf
23. Partnership framework implementation plan in support of South Africa's national HIV, STI and TB response. 2012/13 to 2016/17. (Updated 20 April 2014. Accessed 21 February 2014.) Available from http://www.pepfar.gov/documents/ organization/196651.pdf
24. Vermund SH. Massive benefits of antiretroviral therapy in Africa. J Infect Dis 2014; 209:483-485.
25. Del Rio C, Karim S. Scale-up of ART in South Africa begins to turn the tide. (Accessed 21 February 2014.) Available from http://www.jwatch.org/ ac201303040000001/2013/03/04/scale-art-south-africa-begins-turn-tide
26. Department of Health. National Strategic Plan on HIV, STIs and TB 2012-2016. (Accessed 25 August 2013.) Available from http://laylacassim.co.za/pdf/National%20 Strategic%20Plan%20on%20HIV,%20STIs%20 and%20TB.pdf
27. World Health Organization. Towards the elimination of mother-to-child transmission of HIV. Report of a WHO technical consultation. 9-11 November 2010. (Accessed 23 May 2014.) Available from http://whqlibdoc.who.int/ publications/2011/9789241501910-eng.pdf
28. UNAIDS. Beyond Zero Campaign. (Accessed 13 February 2014.) Available from http://www.unaids.org/en/ targetsandcommitments/eliminatingnewhivinfection amongchildren/
29. Barron P, Pillay Y, Doherty T, et al. Eliminating mother-tochild HIV transmission in South Africa. Bull World Health Organ 2013; 91:70-74
30. National Department of Health. The South African antiretroviral treatment guidelines 2013. (Accessed 21 February 2014.) Available from http://www.sahivsoc.org/ upload/documents/2013%20ART%20Guidelines-Short%20 Combined%20FINAL%20draft%20guidelines%2014%20 March%202013.pdf
31. Dorrington RE, Bradshaw D, Laubscher R. Rapid mortality surveillance report 2012. South African Medical Research Council: Cape Town. (Accessed 23 May 2014.) Available from http://www.mrc.ac.za/bod/ RapidMortalitySurveillanceReport2012.pdf
32. April M, Wood R, Berkowitz B, et al. The survival benefits of antiretroviral therapy in South Africa. J Infect Dis 2013; doi: 10.1093/infdis/jit584.
33. Tanser F, Bärnighausen T, Grapsa E, Zaidi L, Newell M-L. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 2013; 339:966-971.
34. Coovadia HM. Durban conference status, May 2000: interview with conference chair Coovadia. Interview by John S James. AIDS Treat News 2000; 343:4-6.
35. Maurice J. South Africa's battle against HIV/AIDS gains momentum. Lancet 2014; 383:1535-1536.
36. Committee on Examining the Probable Consequences of Alternative Patterns of Widespread Antiretroviral Drug Use in Resource-Constrained Settings. Scaling up treatment for the global AIDS pandemic. Challenges and opportunities. Washington, DC: The National Academies Press 2005.
37. Health Systems Trust. National Health Care Facilities Baseline Audit - National Summary Report. Westville, South Africa. (Updated February 2013. Accessed 20 February 2014.) Available from http://www.sarrahsouthafrica.org/ LinkClick.aspx?fileticket=8a-WvF27C8%3D&tabid=2248
38. Schneider H. On the fault-line: the politics of AIDS policy in contemporary South Africa. Afr Stud 2002; 61:145-167.
39. Fassin D, Schneider H. The politics of AIDS in South Africa: beyond the controversies. BMJ 2003; 326:495-497.
40. Cameron E. The deafening silence of AIDS. Health Hum Rights 2000; 5:7-24.
41. Shisana O, Simbayi LC. Nelson Mandela/HSRC Study of HIV/AIDS: South African national HIV prevalence, behavioural risks and mass media: household survey 2002: executive summary. Cape Town, South Africa: HSRC Press 2002.
42. Shisana O, Rehle T, Simbayi LC, et al. South African national HIV prevalence, HIV incidence, behaviours and communication survey, 2005. Cape Town, South Africa: HSRC Press 2005.
43. Play Your Part. South Africans know your status! (Updated 5 September 2011. Accessed 20 February 2014.) Available from http://www.southafrica.info/playyourpart/hiv-testing. htm#.UizGXxZR6oU
44. Shisana O, Rehle T, Simbayi L, et al. South African national HIV prevalence, incidence, behaviour and communication survey, 2008: a turning tide among teenagers? Cape Town, South Africa: HSRC Press 2009.
45. Johnson S, Kincaid L, Laurence S, Chikwava F, Delate R, Mahlasela L. Second national HIV communication survey 2009. Pretoria, South Africa: Johns Hopkins Health and Education in South Africa 2010.
46. De Lange J. The importance of rapid HIV testing in Africa's resource constrained settings. AFRICAPORTAL, Backgrounder. No 37. August 2012. (Accessed 23 May 2014.) Available from http://www.africaportal.org/sites/ default/files/Africa%20Portal%20Backgrounder%20 No.%2037.pdf
47. Govindasamy D, Van Schaik N, Kranzer K, Wood R, Mathews C, Bekker LG. Linkage to HIV care from a mobile testing unit in South Africa by different CD4 count strata. J Aquir Immune Defic Syndr 2011; 58:344-352.
48. Van Schaik N, Kranzer K, Wood R, Bekker LG. Earlier HIV diagnosis-are mobile services the answer? S Afr Med J 2010; 100:671-674.
49. Nglazi MD, van Schaik N, Kranzer K, Lawn SD, Wood R, Bekker LG. An incentivized HIV counseling and testing program targeting hard-to-reach unemployed men in Cape Town, South Africa. J Acquir Immune Defic Syndr 2012; 59:e28-e34.
50. Pope DS, DeLuca AN, Kali P, et al. A cluster randomized trial of provider-initiated (Opt-out) HIV counseling and testing of tuberculosis patients in South Africa. J Acquir Immune Defic Syndr 2008; 48:190-195.
51. Govindasamy D, Kranzer K, Ford N. Strengthening the HIV cascade to ensure an effective future ART response in sub-Saharan Africa. Trans R Soc Trop Med Hyg 2014; 108:1-3.
52. Kranzer K, Lewis JJ, White RG, et al. Incentivized recruitment of a population sample to a mobile HIV testing service increases the yield of newly diagnosed cases, including those in need of antiretroviral therapy. PLoS ONE 2011; 6:e27763.
53. Bassett IV, Giddy J, Chaisson C, et al. A randomized trial to optimize HIV/TB care in South Africa: design of the Sizanani trial. BMC Infect Dis 2013; 13:390.
54. Khumalo-Sakutukwa G, Morin SF, Fritz K, et al. Project Accept (HPTN 043): a community-based intervention to reduce HIV incidence in populations at risk for HIV in sub-Saharan Africa and Thailand. J Acquir Immune Defic Syndr 2008; 49:422-431.
55. Myer L, Rabkin M, Abrams EJ, Rosenfield A, Sadr WEM. Focus on women: linking HIV care and treatment with reproductive health services in the MTCT-Plus Initiative. Reproductive Health Matters 2005; 13:136-146.
56. World Health Organization. Workshop to scale up the implementation of TB/HIV integration in Africa. 2013. (Accessed 23 May 2014.) Available from http://www.who. int/hiv/pub/meetingreports/maputo-access/en/
57. Boulle A, Bock P, Osler M, et al. Antiretroviral therapy and early mortality in South Africa. Bull World Health Organ 2008; 86:678-687.
58. Lahuerta M. Median CD4 count increase modest at ART initiation in sub-Saharan Africa. Clin Infec Dis 2013; doi: 10.1093/cid/cit724.
59. Larson BA, Schnippel K, Ndibongo B, et al. Rapid point-of-care CD4 testing at mobile HIV testing sites to increase linkage to care: an evaluation of a pilot program in South Africa. J Acquir Immune Defic Syndr 2012; 61:e13-e17.
60. Lahuerta M, Ue F, Hoffman S, et al. The problem of late ART initiation in SSA: a transient aspect of scale up or a long-term phenomenon? J Health Care Poor Underserved 2013; 24:359-383.
61. st Southern African HIV Clinicians Society Conference. 25 November 2012, Cape Town, South Africa.
62. Nglazi MD, Lawn SD, Kaplan R, et al. Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa. J Acquir Immune Defic Syndr 2011; 56:e1-e8.
63. Boulle A, Van Cutsem G, Hilderbrand K, et al. Seven year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS 2010; 24:563-572.
64. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health 2010; 15 Suppl 1:1-15.
65. Cornell M, Grimsrud A, Fairall L, et al. Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS 2010; 24:2263-2270.
66. Wilkinson LS. ART adherence clubs: a long-term retention strategy for clinically stable patients receiving antiretroviral therapy. South Afr J HIV Med 2013; 14:48-50.
67. Luque-Fernandez MA, Van Cutsem G, Goemaere E, et al. Effectiveness of patient adherence groups as a model of care for stable patients on antiretroviral therapy in Khayelitsha, Cape Town, South Africa. PLoS ONE 2013; 8:e56088.
68. Wilkinson L. ART adherence clubs: a long-term retention strategy for clinically stable patients receiving antiretroviral therapy. South Afr J HIV Med 2013; 14:48-50.
69. Grimsrud A, Patten G, Sharp J, Myer L, Wilkinson L, Bekker LG. Extending dispensing intervals for stable patients on ART. J Acquir Immune Defic Syndr 2014; 66:e58-e60.
70. South African National Department of Health. National Drug Policy for South Africa. 1996. (Accessed 20 February 2014.) Available from http://apps.who.int/medicinedocs/ documents/s17744en/s17744en.pdf
71. Klug H. Access to medicines and the transformation of the South African state: exploring the interactions of legal and policy changes in health, intellectual property, trade, and competition law in the context of South Africa's HIV/AIDS pandemic. Law Soc Inq 2012; 37:297-329.
72. Wirtz VJ, Forsythe S, Valencia-Mendoza A, Bautista-Arredondo S. Factors influencing global antiretroviral procurement prices. BMC Public Health 2009; 9 Suppl 1:S6. 73. South African HIV Clinicians Society. Fixed-dose combination for adults accessing antiretroviral therapy. South Afr J HIV Med 2013; 14:41-43.
73. Médecins Sans Frontières. Rural health advocacy project, section 27, treatment action campaign. Emergency intervention at Mthatha Depot: the hidden cost of inaction. 2013. (Accessed 24 May 2014.) Available from http://www.section27.org.za/wp-content/uploads/2013/01/ Report-Emergency-Intervention-at-Mthatha-Depot-Jan-2013-Final-.pdf
74. Southern African HIV Clinicians Society. Red flag drugs stock-out list. (Updated 26 May 2013. Accessed 24 May 2014.) Available from http://www.sahivsoc.org/stockouts
75. Hamers RL, Sigaloff KC, Kityo C, Mugyenyi P, de Wit TF. Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa. Curr Opin HIV AIDS 2013; 8:19-26.
76. Sprague C, Chersich MF, Black V. Health system weaknesses constrain access to PMTCT and maternal HIV services in South Africa: a qualitative enquiry. AIDS Res Ther 2011; 8:10.
77. Nglazi MD, Kaplan R, Wood R, et al. Identification of losses to follow-up in a community-based antiretroviral therapy clinic in South Africa using a computerized pharmacy tracking system. BMC Infect Dis 2010; 10:329.
78. Orrell C, Dipenaar R, Killa N, et al. Simplifying HIV cohort monitoring-pharmacy stock records minimize resources necessary to determine retention in care. J Acquir Immune Defic Syndr 2013; 62:e106-e108.
79. WHO and UNICEF. Evaluation of management and supply systems for ARV in west and central Africa. (Accessed 20 February 2014.) Available from http://apps.who.int/ medicinedocs/documents/s16466e/s16466e.pdf
80. WHO. 2009 Recommendations for antiretroviral therapy in adults and adolescents: summary of WHO rapid advice. (Accessed 21 February 2014.) Available from http://www. who.int/hiv/topics/treatment/summary-rapid-advice.pdf?ua=1
81. UNAIDS. Access to antiretroviral therapy in Africa: status report on progress towards the 2015 targets. (Accessed 24 May 2014.) Available from http://www.unaids.org/en/media/unaids/ contentassets/documents/unaidspublication/2013/20131219- AccessARTAfricaStatusReportProgresstowards2015Targets- en.pdf
82. WHO. WHO report: global update on HIV treatment 2013: results, impact and opportunities June 2013. (Accessed 24 May 2014.) Available from http://www. unaids.org/en/media/unaids/contentassets/documents/ unaidspublication/2013/20130630-treatment-report-en.pdf
83. Beaubien J. South Africa weighs starting HIV drug treatment sooner. (Updated 16 July 2013. Accessed 12 December 2013.) Available from http://www.npr.org/blogs/ health/2013/07/16/202381945/south-africa-weighs-starting-hiv-drug-treatment-sooner
84. Gallant JE, Mehta S, Sugarman J. Universal antiretroviral therapy for HIV infection: should US treatment guidelines be applied to resource-limited settings? Clin Infect Dis 2013; 57:884-887. 86. Cohen J. Treatment as prevention. Science 2011; 334:1628.
85. i-base. START (Strategic Timing of AntiRetroviral Treatment) Study. (Updated February 2013. Accessed 24 February 2014.) Available from http://i-base.info/start-study/
86. Geffen, N. When to start ART in adults? The results of HPTN 052 move us closer to a test-and-treat policy. South Afr J HIV Med 2011; 12:9.
87. AVAC. Ongoing and planned treatment as prevention studies. (Accessed 20 February 2014.) Available from http:// www.avac.org/ht/a/GetDocumentAction/i/33215
88. Republic of South Africa National Planning Commission. National Development Plan 2030. (Accessed 22 February 2014.) Available from http://www.npconline.co.za/medialib/ downloads/home/NPC%20National%20Development%20 Plan%20Vision%202030%20-lo-res.pdf
89. Republic of South Africa National Planning Commission. South Africa's troubles: a diagnostic overview. (Accessed 18 September 2014.) Available from http://www. politicsweb.co.za/politicsweb/view/politicsweb/en/ page71656?oid=240416&sn=Detail
90. Long L, Brennan A, Fox MP, et al. Treatment outcomes and cost-effectiveness of shifting management of stable ART patients to nurses in South Africa: an observational cohort. PLoS Med 2011; 8:e1001055.
91. Lynch S, Ford N, Van Cutsem G, et al. Getting HIV treatment to the most people. Science 2012; 337:298-300.
92. Bekker L-G, Myer L, Orrell C, et al. Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. S Afr Med J 2006 96:315-320.
93. Fatti G, Grimwood A, Bock P. Better antiretroviral therapy outcomes at primary healthcare facilities: an evaluation of three tiers of ART services in four South African provinces. PLoS ONE 2010; 5:e12888.
94. Geng EH, Nash D, Kambugu A, et al. Retention in care among HIV-infected patients in resource-limited settings: emerging insights and new directions. Curr HIV/AIDS Rep 2010; 7:234-244.
95. Treatment Action Campaign. South African ARV sites - February 2008. (Accessed 13 November 2013.) Available from www.tac.org.za/documents/arvsitesfebruary2008.pdf
96. Black S, Zulliger R, Myer L, et al. Safety, feasibility and efficacy of a rapid ART initiation in pregnancy pilot program in Cape Town, South Africa. S Afr Med J 2013; 103:557-562.
97. Lawn SD, Campbell L, Kaplan R, et al. Delays in starting antiretroviral therapy in patients with HIV-associated tuberculosis accessing non-integrated clinical services in a South African township. BMC Infect Dis 2011; 11:258.
98. Besada D, Van Cutsem G, Goemaere E, N Ford, H Bygrave, S Lynch. The case for Option B and Optional B+: ensuring that South Africa's commitment to eliminating mother-tochild transmission of HIV becomes a reality. South Afr J HIV Med 2012; 13:178.
99. Sanne I, Orrell C, Fox MP, et al. Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised noninferiority trial. Lancet 2010b; 376:33-40.
100. Long L, Brennan A, Fox MP, et al. Treatment outcomes and cost-effectiveness of shifting management of stable ART patients to nurses in South Africa: an observational cohort. PLoS Med 2011; 8:e1001055.
101. Gilks CF, Crowley S, Ekpini R, et al. The WHO publichealth approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368:505-510.
102. Schneider H, Blaauw D, Gilson L, et al. Health systems and access to antiretroviral drugs for HIV in Southern Africa: service delivery and human resources challenges. Reprod Health Matters 2006; 14:12-23.
103. World Health Organization. Global tuberculosis report 2013. (Accessed 13 November 2013.) Available from http://apps.who.int/iris/ bitstream/10665/91355/1/9789241564656-eng.pdf
104. Wood R, Lawn S, Johnstone-Robertson S, Bekker LG. Tuberculosis control has failed in South Africa - time to reappraise strategy. S Afr Med J 2011; 101:111-114.
105. Nglazi MD, Kaplan R, Caldwell J, et al. Antiretroviral treatment uptake in patients with HIV-associated TB attending co-located TB and ART services. S Afr Med J 2012; 102:936-939.
106. Bekker LG, Wood R. Community based management of multi-drug resistant tuberculosis in South Africa. Int J Tuberc Lung Dis 2010; 14:379.
107. NHLS. NHLS Annual report 2012-2013. (Accessed 24 February 2013.) Available from http://www.nhls.ac.za/ assets/files/NHLS-AR2012-13.pdf
108. rd Edition. (Accessed 13 November 2013.) Available from http://www.unitaid.org/images/marketdynamics/ publications/UNITAID-HIV-Diagnostic-Landscape-3rd- edition.pdf
109. Roberts T, Bygrave H, Fajardo E, Ford N. Challenges and opportunities for the implementation of virological testing in resource-limited settings. J Int AIDS Soc 2012; 15: 17324.
110. Médecins Sans Frontières. Undetectable: how viral load monitoring can improve HIV treatment in developing countries. (Updated 23 July 2012. Accessed 27 June 2013.) Available from http://www.msfaccess.org/content/ undetectable-how-viral-load-monitoring-can-improve-hiv-treatment-developing-countries
111. Wu G, Zaman H. Low cost tools for diagnosing and monitoring HIV infection in low-resource settings. Bull World Health Organ 2012; 90:914-920.
112. Schito M, Peter TF, Cavanaugh S, et al. Opportunities and challenges for cost-efficient implementation of new point-of-care diagnostics for HIV and tuberculosis. J Infect Dis 2012; 205 Suppl 2:S169-S180.
113. Sherman GG, Stevens G, Jones SA, et al. Dried blood spots improve access to HIV diagnosis and care for infants in low-resource settings. J Acquir Immune Defic Syndr 2005; 38:615-617.
114. Bennet DE, Myatt M, Sutherland D, Gilks C. Recommendations for surveillance of transmitted drug resistant virus in countries scaling up ART. Antivir Ther 2008; 13 Suppl 2:25-36.
115. Jacobs GB, Laten A, Janse van Rensburg E, et al. Phylogenetic diversity and low level antiretroviral resistance mutations in HIV type 1 treatment-naive patients from Cape Town, South Africa. AIDS Res Hum Retroviruses 2008; 24:1009-1012.
116. Cornell M, Technau K, Fairall L, et al. Monitoring the South African National Antiretroviral Treatment Programme, 2003-2007: The IeDEA Southern Africa Collaboration. S Afr Med J 2009; 99:653-660.
117. Fatti G, Grimwood A, Bock P. Better antiretroviral therapy outcomes at primary healthcare facilities: an evaluation of three tiers of ART services in four South African provinces. PLoS ONE 5:e12888.
118. Fairall LR, Bachmann MO, Louwagie GM, et al. Effectiveness of antiretroviral treatment in a South African program: a cohort study. Arch Intern Med 2008; 168: 86-93.
119. Bradshaw D, Dorrington RE, Laubscher R. Rapid mortality surveillance report 2011. Cape Town: South African Medical Research Council 2012.
120. Bekker LG, Wood R. Do we need a national antiretroviral treatment register? S Afr Med J 2003; 93:514-515.
121. NPR Staff. How the US helped fight the global AIDS epidemic. (Accessed 24 May 2014.) Available from http:// www.npr.org/blogs/health/2013/12/17/251950362/how-the-u-s-helped-to-fight-the-global-aids-epidemic
122. The President's Emergency Plan for AIDS Relief (PEPFAR) blueprint. Creating an AIDS-free generation. (Accessed 24 May 2014.) Available from http://www.pepfar.gov/ documents/organization/201386.pdf
123. US Government. Statement from Ambassador Eric Goosby. MD, US Global AIDS Coordinator, on WHO Guidelines on HIV. (Updated 2 July 2013. Accessed 20 November 2013.) Available http://www.pepfar.gov/press/ releases/2013/211470.htm
124. Novario P, Bekker L-G, Blecher M, et al. Special report on the state of HIV/AIDS in South Africa. (Accessed 20 February 2014.) Available from http://www.cssr.uct.ac.za/ sites/cssr.uct.ac.za/files/pubs/South-Africa-HIV-strategy- GHMag.pdf
125. Bor J, Herbst AJ, Newell M-L, Bärnighausen T. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science 2013; 339:961-965.
126. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2197-2223.
127. Ortblad KF, Lozano R, Murray CJ. The burden of HIV: insights from the Global Burden of Disease Study. AIDS 2013 27:2003-2017.
128. Abdool Karim SS, Churchyard GJ, Abdool Karim Q, Lawn SD. HIV and TB in South Africa: an urgent need to escalate the public health response. Lancet 2009; 374:921-933.